Abstract
To test the potential of immunoreactive BSP, a non-collagenous bone matrix component, as a clinical guide in patients with plasma cell dyscrasias, serum BSP concentrations were measured in 62 patients with newly diagnosed multiple myeloma (MM) followed over a period of 4 years, in 46 patients with monoclonal gammopathy of undetermined significance (MGUS), in 71 patients with untreated benign vertebral osteoporosis (OPO), and in 139 healthy adults. Results were compared with clinical and laboratory data, including serum osteocalcin (OC), and urinary pyridinoline (PYD) and deoxypyridinoline (DPD) as markers of bone turnover. In MM, serum BSP, and urinary PYD and DPD were higher than in healthy controls and in MGUS or OPO (P< 0.001). BSP levels correlated with the bone marrow plasma cell content (r = 0.40, P< 0.001), and serum β2-microglobulin (r = 0.31, P < 0.01). The differentiation of MM from healthy controls and from MGUS or OPO was highest for BSP. After chemotherapy, BSP reflected the response to treatment and correlated with the change in monoclonal protein (r = 0.55, P< 0.001). MM patients with normal baseline BSP levels survived longer than patients with initially elevated BSP values (P< 0.001, logrank test). Only serum monoclonal protein and BSP were independent predictors of survival. We conclude that in MM, BSP levels are associated with skeletal involvement and tumour cell burden. The quantification of serum BSP may be a non-invasive method for the diagnosis and follow-up, and may improve the prognostic value of conventional staging in MM. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bataille R, Chappard D, Alexandre C and Sany J (1986) Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 53: 805–810
Bataille R, Chappard D, Marcelli C, Dessauw PH, Baldet P, Alexandre C and Sany J (1989) Mechanism of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7: 1909–1914
Bataille R, Delmas PD, Chappard D and Sany J (1990) Abnormal serum bone Gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 66: 167–172
Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J and Alexandre C (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88: 62–66
Bataille R, Chappard D and Basle MF (1996) Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 87: 4762–4769
Bataille R, Manolagas SC and Berenson JR (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol Oncol Clin North Am 11: 349–361
Bellahcène A, Merville MP and Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54: 2823–2826
Bellahcène A, Kroll M, Liebens F and Castronovo V (1996a) Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11: 665–670
Bellahcène A, van Riet I, Antoine N, van Camp B and Castronovo V (1996b) Expression of bone sialoprotein in myeloma cell lines. Proc Annu Meet Am Assoc Cancer Res 37: 618 (abstr)
Black D, Duncan A and Robins SP (1988) Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169: 197–203
Bladé J and Kyle RA (1995) Monoclonal gammopathies of undetermined significance. Myeloma. Biology and Management, Malpas JS, Bergsagel DE, Kyle RA (eds) pp. 433. Oxford University Press: Oxford
Chen JK, Shapiro HS, Wrana JL, Reimers S, Heersche JN and Sodek J (1991) Localization of bone sialoprotein (BSP) expression to sites of mineralized tissue formation in fetal rat tissues by in situ hybridization. Matrix 11: 133–143
Coleman RE (1997) Skeletal complications of malignancy. Cancer 80: 1588–1594
Diel IJ, Solomayer EF, Seibel M, Pfeilschifter J, Gollan C, Conradi R, Meisenbacher H, Naser W, Hoyle N and Bastert G (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919
Durie BGM and Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36: 842–854
Elomaa I, Virkkunen P, Risteli L and Risteli J (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 66: 337–341
Fisher LW, Whitson SW, Avioli LW and Termine JD (1983) Matrix sialoprotein of developing bone. J Biol Chem 258: 12723–12727
Fisher LW, Hawkins GR, Tuross N and Termine JD (1987) Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 262: 9702–9708
Fujisawa R, Butler WT, Brunn JC, Zhou HY and Kuboki Y (1993) Differences in composition of cell-attachment sialoproteins between dentin and bone. J Dent Res 72: 1222–1226
Heinegard D and Oldberg A (1989) Structure and biology of cartilage and bone matrix noncollageneous macromolecules. FASEB J 3: 2042–2051
Helfrich MH, Nesbitt SA, Dorey EL and Horton MA (1992) Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res 7: 335–343
Karmatschek M, Maier I, Seibel MJ, Woitge HW, Ziegler R and Armbruster FP (1997) Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin Chem 43: 2076–2082
Malpas JS (1995) Clinical presentation and diagnosis. In: Myeloma Biology and Management, Malpas JS, Bergsagel DE, Kyle RA (eds) pp. 1995. Oxford University Press: Oxford
Mundy GR and Yoneda T (1998) Bisphosphonates as anticancer drugs. New Engl J Med 339: 398–400
Oldberg A, Franzen A, Heinegard D, Pierschbacher M and Ruoslahti E (1988) Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 263: 19433–19436
Pecherstorfer M, Seibel MJ, Woitge HW, Horn E, Schuster J, Neuda J, Sagaster P, Köhn H, Bayer P, Thiébaud D and Ludwig H (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium crosslinks of collagen. Blood 90: 3743–3750
Raynal C, Delmas PD and Chenu C (1996) Bone sialoprotein stimulates in vitro bone resorption. Endocrinology 137: 2347–2354
Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL and Cheresh DA (1993) Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 268: 9901–9907
Salmon SE and Cassady JR (1993) Plasma cell neoplasms. In: Cancer: Principles and Practice in Oncology, Vol 2, De Vita VT, Hellmann S, Rosenberg SA (eds) pp. 1984. Lippincott: Philadelphia
Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP and Ziegler R (1996) Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81: 3289–3294
Shapiro HS, Chen J, Wrana JL, Zhang Q, Blum M and Sodek J (1993) Characterization of porcine bone sialoprotein: primary structure and cellular expression. Matrix 13: 431–440
Teoh G and Anderson KC (1997) Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11: 27–42
Uchiyama H, Barut BA and Mohrbacher AF (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82: 3712–3720
Van Riet I and Van Camp B (1993) The involvement of adhesion molecules in the biology of multiple myeloma. Leuk Lymphoma 9: 441–452
Van Riet I, Vanderkerken K, de Greef C and Van Camp B (1998) Homing behavior of the malignant cell clone in multiple myeloma. Med Oncol 15: 154–164
Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, deLeval J and Castronovo V (1998) Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90: 1000–1008
Woitge HW, Pecherstorfer M, Li Y, Keck A-V, Horn E, Ziegler R and Seibel MJ (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792–801
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Woitge, H., Pecherstorfer, M., Horn, E. et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84, 344–351 (2001). https://doi.org/10.1054/bjoc.2000.1614
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1614
Keywords
This article is cited by
-
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
Leukemia (2010)
-
Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer
Nature Reviews Cancer (2008)
-
Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis
Clinical & Experimental Metastasis (2008)
-
Clinical use of markers of bone turnover in metastatic bone disease
Nature Clinical Practice Oncology (2005)
-
Collagen crosslink excretion and staging of oral cancer
British Journal of Cancer (2003)